Cardiology Update

JANUARY 22, 2024

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). in the ICD group and 75.4%

Heart Failure 115

Heart Failure Defibrillator Heart Transplant Transplant 115

European Journal of Heart Failure

NOVEMBER 11, 2024

Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx).

Heart Transplant 40

Heart Transplant Transplant Heart Failure Ablation 40

MIBHS

OCTOBER 31, 2024

Dilation: The chambers of the heart expand, making the walls thinner. Both forms of enlargement may compromise the heart’s ability to pump blood efficiently, leading to further complications like heart failure. What Causes an Enlarged Heart? Here are some of the most common causes: 1.

Blood Pressure 52

Blood Pressure Blood Clot Heart Valves Heart Rhythm 52

European Journal of Heart Failure

NOVEMBER 9, 2023

Abstract Aim Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heart failure in patients with a broad or paced QRS. The primary composite endpoint included all-cause mortality, heart transplantation, or ventricular assist device implantation. ml/min/1.73 m ml/min/1.73 m

Outcomes 40

Outcomes Heart Failure Heart Transplant Defibrillator 40

Dr. Sanjay Gupta

MARCH 6, 2022

So she went back in 4 weeks and this time saw another doctor who asked her to stop the inhalers and suggested that it could be her heart and organised a chest X-ray and blood tests. Medications that improve quality of life in heart failure for example include diuretics.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

European Journal of Heart Failure

DECEMBER 1, 2024

Methods and results This single-centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. Functional status was assessed with New York Heart Association (NYHA) classification. years, 80% male) received Impella 5+ and discharged with heart recovery.

Cardiogenic Shock 40

Cardiogenic Shock Heart Transplant Outcomes Transplant 40